
JoannaOsmanska
@jo_osmanska
Passionate about cardiology and research. Views of my own
ID: 1177936274122035202
28-09-2019 13:21:16
237 Tweet
329 Followers
522 Following

👉 Biomarkers of lung congestion and injury in acute heart failure. Read all about it in #ESCHeartFailure bit.ly/3ySBifw EJHF Editor-in-Chief Jan Biegus #HFA_ESC Harriette Van Spall, MD MPH 🇨🇦 Shelley Zieroth Marat Fudim, MD MHS Gregg Fonarow MD Jozine ter Maaten Amr Abdin Giuseppe Galati Henry Han Wilfried Mullens


Being presented at #ESCCongress ⬇️ Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis hubs.li/Q02M1wzF0 European Society of Cardiology


NHS Research Scotland opportunities for associate PI apprenticeships! Can here more about it at the trainee meeting in Perth


What’s new in #HF Oct 2024? doi.org/10.1002/ejhf.3… #Finerenone #FINEARTS-HF #FINE-HEART #Semaglutide #STEP-#HFpEF #SELECT #FLOW #MitraClip #RESHAPE-HF2 #MATTERHORN #Vutrisiran #HELIOS-B #Aficamten #SEQUOIA-#HCM #FOREST-HCM Pau Codina Verdaguer Daniela Tomasoni Alberto Aimo European Society of Cardiology Journals



Register now for the 2025 Heart Failure Hub Scotland annual Ensuring success with #HeartFailure conference Register here eventbrite.com/e/11th-annual-… Royal College of Physicians & Surgeons of Glasgow Leeanne Macklin


Great discussions with great colleagues on current and future challenges of real world evidence, including pragmatic trials CVCT - CardioVascular Clinical Trialists #CVCT2024



Cardiovascular trials still under-represent diverse groups relative to population disease distribution. In Nature Medicine, Otavio Berwanger, Harriette Van Spall, MD MPH 🇨🇦, and Faiez ZANNAD share insights on making clinical trials in this field more inclusive. Read more: buff.ly/48kV40B



EMPRESS-MI: Empagliflozin vs placebo, n=105 w/ LVSD (mean LVEF 34.8%) post-AMI (24wks): ↔️LVESVI, LVEDVI, LVEF, LAVI, LVMI ↔️NT-proBNP, hs-TnI ↗️Hct ↘️urate, weight 🔗 doi.org/10.1002/ejhf.3… Jaclyn Carberry Kieran Docherty Mark Petrie Colin Berry University of Glasgow Heart Failure Research Group UofG SCMH


Torsemide is proposed to have clinically important pharmacokinetic and pharmacodynamic advantages over furosemide. This study found no meaningful pharmacokinetic/pharmacodynamic advantages for torsemide versus furosemide. bit.ly/JASN0481 Cleveland Clinic Cleveland Clinic MD


🗞️ SUGAR-DM-HF #CMR estimated PCWP & congestion markers, and effect of #empagliflozin in #HFrEF with dysglycaemia European Society of Cardiology Journals Giuseppe Galati Amr Abdin Henry Han HFAPresident bit.ly/3C55VQt


📌Standardized Definitions of Changes in Kidney Function in Trials of #HeartFailure: JACC Journals Expert Panel From the #HFARC #CardioRenal #ClinicalTrials #HF #CKD


🚨 New HFA/ESC consensus statement! 🚨 Clinical management & therapy optimization for HFrEF patients with low BP—practical guidance for safer, more effective treatment. 📄👇 #HeartFailure ow.ly/IzyB50Va9rJ Amr Abdin Giuseppe Galati Henry Han Dr. Hadi Skouri EJHF Editor-in-Chief #EJHF


Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction in EHJ. doi.org/10.1093/eurhea… @ESCardio European Society of Cardiology Journals #age #5UDMI John William McEvoy


Join us tomorrow for the #HFA_ESC webinar: "Heart Failure in the Community" 📌 3 June 2025 | 18.00-19.00 CET 🎙️Faculty: Amina, Kieran Docherty, Maggie Simpson, Dr Klaus Witte MD 🔗 Register now: esc365.escardio.org/event/1974 European Society of Cardiology
